Outcome of two patients harboring EML4-ALK fusion gene with brain metastasis treated with crizotinib

被引：0
|
作者：
Okimoto, Tamio [1 ]
Tsubata, Yukari [1 ]
Nakao, Mika [1 ]
Koba, Naoya [1 ]
Hotta, Takamasa [1 ]
Hamaguchi, Megumi [1 ]
Hamaguchi, Shunnichi [1 ]
Sutani, Akihisa [1 ]
Hamada, Akinobu [2 ]
Isobe, Takeshi [1 ]
机构：
[1] Shimane Univ, Sch Med, Dept Internal Med, Div Clin Oncol & Resp Med, Matsue, Shimane, Japan
[2] Natl Canc Ctr, Res Inst, Ctr Translat Res Core, Dept Clin Pharmacol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-1-56
引用
下载
收藏
页码：137 / 138
页数：2
相关论文
共 50 条
  • [21] Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
    Hong Tao
    Zhe Liu
    Jing Mu
    Fei Gai
    Zhan Huang
    Liang Shi
    Diagnostic Pathology, 17
  • [22] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Burak Bilgin
    Mehmet Ali Nahit Şendur
    Şebnem Yücel
    Mutlu Hizal
    Gürkan Güner
    Nalan Akyürek
    Cihan Erol
    Muhammed Bülent Akıncı
    Didem Şener Dede
    Bülent Yalçın
    Sadettin Kılıçkap
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2637 - 2643
  • [23] Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
    Tao, Hong
    Liu, Zhe
    Mu, Jing
    Gai, Fei
    Huang, Zhan
    Shi, Liang
    DIAGNOSTIC PATHOLOGY, 2022, 17 (01)
  • [24] Clinicopathological features of younger (aged 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene
    Kometani, Takuro
    Sugio, Kenji
    Osoegawa, Atsushi
    Seto, Takashi
    Ichinose, Yukito
    THORACIC CANCER, 2018, 9 (05) : 563 - 570
  • [25] A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene
    Chen, Xiaoxia
    Zhang, Jie
    Hu, Qiong
    Li, Xuefei
    Zhou, Caicun
    LUNG CANCER, 2013, 81 (02) : 308 - 310
  • [26] EML4-ALK FUSION GENE IN LUNG ADENOCARCINOMA IN THAILAND
    Prempree, Thongbliew
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1023 - S1024
  • [27] A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4-ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib
    Omachi, Naoki
    Shimizu, Shigeki
    Kawaguchi, Tomoya
    Tezuka, Kenji
    Kanazu, Masaki
    Tamiya, Akihiro
    Asami, Kazuhiro
    Okishio, Kyoichi
    Kitaichi, Masanori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (06) : E40 - E42
  • [28] Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients (NSCLC)
    Aguado, Cristina
    Teixido, Cristina
    Gimenez-Capitan, Ana
    Gil, Maria de los Llanos
    Rodriguez, Sonia
    Viteri, Santiago
    Karachaliou, Niki
    Aldeguer, Erika
    Peg, Vicente
    Alonso, Lidia
    Molina-Vila, Miguel Angel
    Rosell, Rafael
    CANCER RESEARCH, 2017, 77
  • [29] Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Transtocation with Adnexal Metastasis
    Wang, Wenxian
    Jin, Ying
    Zhang, Yiping
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1176 - S1176
  • [30] A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK
    Anai, Satoshi
    Takeshita, Masafumi
    Ando, Nobuhisa
    Ikematsu, Yuuki
    Mishima, Shohei
    Ishida, Koichi
    Inoue, Kouji
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : E126 - +
12345